About Us
Precision Healing Reimagined
Tozho is a biotechnology company pioneering advanced regenerative therapies using engineered extracellular vesicles (EVs). By combining immune-evasive technology, such as CD47 functionalization, with pro-healing enzymes like thymidine phosphorylase, Tozho delivers targeted, cell-free treatments designed to accelerate wound healing and overcome chronic inflammation.
Our proprietary, scalable platform positions Tozho at the forefront of precision biology, transforming how chronic wounds are treated and restored.
Sign up for Updates
Stay informed—sign up for email updates on Tozho’s
breakthroughs and biotech innovations.
Our Science
Engineered Vesicles. Scalable Impact.
Tozho’s platform leverages mesenchymal stem cell–derived extracellular vesicles (MSC-EVs) engineered for enhanced therapeutic function. Through stable encapsulation of thymidine phosphorylase and surface expression of CD47, these EVs promote angiogenesis while evading phagocytic clearance.
Utilizing serum-free, microalgal-enhanced culture and a proprietary chitin-based isolation method, Tozho achieves high-yield, GMP-adaptable EV production—enabling a robust, scalable approach to modulating wound microenvironments and advancing regenerative medicine.